{
    "name": "immune globulin IV (IGIV)",
    "comment": "Rx",
    "other_names": [
        "Gammagard S/D",
        "Carimune NF",
        "Carimune",
        "Bivigam",
        "Flebogamma",
        "Gammagard",
        "Gammaplex",
        "Gamunex-C",
        "IV Immune Globulin",
        "IVIG",
        "Octagam",
        "Privigen",
        "Flebogamma 10% DIF",
        "Flebogamma 5% DIF",
        "Gammaked",
        "Panzyga",
        "Asceniv"
    ],
    "classes": [
        "Immune Globulins"
    ],
    "source": "https://reference.medscape.com/drug/gammagard-s-d-carimune-nf-immune-globulin-iv-igiv-343138",
    "pregnancy": {
        "common": [
            "No human data are available to indicate the presence or absence of drug-associated risk",
            "Animal reproduction studies have not been conducted",
            "Unknown if immune globulin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity",
            "Immune globulins cross the placenta from maternal circulation increasingly after 30 weeks of gestation"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "No human data are available to indicate the presence or absence drug-associated risk",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Acute renal dysfunction and renal failure",
                    "description": [
                        "Associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death",
                        "Administer IV at minimum concentration available and minimum rate of infusion in patients predisposed to acute renal failure; IVIG products containing sucrose as a stabilizer or at daily doses >400 mg/kg account for a disproportionate share of case reports involving renal failure",
                        "Patients predisposed to acute renal failure",
                        "Any degree of preexisting renal insufficiency",
                        "Diabetes mellitus",
                        "Age >65 years",
                        "Volume depletion",
                        "Sepsis",
                        "Paraproteinemia",
                        "Currently taking nephrotoxic drugs"
                    ]
                },
                {
                    "type": "Thrombosis",
                    "description": [
                        "Any degree of preexisting renal insufficiency",
                        "Diabetes mellitus",
                        "Age >65 years",
                        "Volume depletion",
                        "Sepsis",
                        "Paraproteinemia",
                        "Currently taking nephrotoxic drugs"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to gamma globulin, thimerosal",
                "Isolated IgA deficiency",
                "Hyperprolinemia (Privigen)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Risk of transmitting infectious agents (eg, viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent); all infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider",
                "Severe hypersensitivity reactions may occur; in case of hypersensitivity, discontinue the Privigen infusion immediately and institute appropriate treatment (see Contraindications)",
                "Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IGIV) products in predisposed patients (see Black Box Warnings)",
                "Aseptic meningitis syndrome (AMS) may occur infrequently following treatment with immune globulin products; discontinuation of treatment has resulted in remission of AMS within several days without sequelae; AMS usually begins within several hours to 2 days following IGIV treatment",
                "Hyperproteinemia, increased serum viscosity, and hyponatremia may occur following treatment with IGIV products",
                "Hemolytic anemia can develop subsequent to IGIV therapy due to enhanced RBC sequestration; IGIV recipients should be monitored for clinical signs and symptoms of hemolysis; if signs and/or symptoms of hemolysis are present after IGIV infusion, appropriate confirmatory laboratory testing should be done",
                "Postpone live virus vaccines for at least 3 months",
                "Maltose-containing brands may give false high for glucose in certain glucose-testing systems",
                "Various passively transferred antibodies in immunoglobulin preparations may lead to misinterpretation of the results of serological testing"
            ],
            "specific": [
                {
                    "type": "Transfusion-Related Acute Lung Injury (TRALI)",
                    "description": [
                        "Noncardiogenic pulmonary edema may occur following treatment with IGIV products  TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever",
                        "Symptoms typically appear within 1-6 hr following treatment; monitor patients for pulmonary adverse reactions",
                        "If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies and anti-human leukocyte antigen (HLA) antibodies in both the product and the patient's serum",
                        "TRALI may be managed using oxygen therapy with adequate ventilatory support"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "immune globulin IV (IGIV), axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bacitracin",
            "description": {
                "common": "immune globulin IV (IGIV) and bacitracin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug. Avoid concurrent use of bacitracin with other nephrotoxic drugs"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "immune globulin IV (IGIV), brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "immune globulin IV (IGIV), ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "immune globulin IV (IGIV), idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "immune globulin IV (IGIV), lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "immune globulin IV (IGIV), tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "immune globulin IV (IGIV) decreases effects of BCG vaccine live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of immune globulin IV (IGIV) by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "immune globulin IV (IGIV) decreases effects of measles (rubeola) vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "immune globulin IV (IGIV) decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "immune globulin IV (IGIV) decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peramivir",
            "description": {
                "common": "immune globulin IV (IGIV) increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "immune globulin IV (IGIV) decreases effects of rubella vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "immune globulin IV (IGIV) decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "immune globulin IV (IGIV) decreases effects of varicella virus vaccine live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethotoin",
            "description": {
                "common": "ethotoin, immune globulin IV (IGIV). Mechanism: unknown. Minor/Significance Unknown. Risk of hypersensitivity myocarditis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin, immune globulin IV (IGIV). Mechanism: unknown. Minor/Significance Unknown. Risk of hypersensitivity myocarditis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin, immune globulin IV (IGIV). Mechanism: unknown. Minor/Significance Unknown. Risk of hypersensitivity myocarditis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "protein a column",
            "description": {
                "common": "protein a column decreases levels of immune globulin IV (IGIV) by Other (see comment). Minor/Significance Unknown. \nComment: Since Prosorba binds IgG, it could theoretically interfere with the levels and/or effects of pharmacologic immune globulins."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "45"
        },
        {
            "name": "Fatigue",
            "percent": "16.3"
        },
        {
            "name": "Nausea",
            "percent": "13.8"
        },
        {
            "name": "Chills",
            "percent": "11.3"
        },
        {
            "name": "Vomiting",
            "percent": "11.3"
        },
        {
            "name": "Headache",
            "percent": "21.7"
        },
        {
            "name": "Pyrexia",
            "percent": "19.6"
        },
        {
            "name": "Pain",
            "percent": "15.2"
        },
        {
            "name": "Injection site reaction",
            "percent": "13"
        },
        {
            "name": "Headache",
            "percent": "24"
        },
        {
            "name": "Back pain",
            "percent": "10"
        },
        {
            "name": "Pain",
            "percent": "8.8"
        },
        {
            "name": "Elevated body temperature",
            "percent": "8.8"
        },
        {
            "name": "Diarrhea",
            "percent": "7.5"
        },
        {
            "name": "Cough",
            "percent": "6.3"
        },
        {
            "name": "Stomach discomfort",
            "percent": "6.3"
        },
        {
            "name": "Blood total bilirubin increased",
            "percent": "5.3"
        },
        {
            "name": "Hematocrit decreased",
            "percent": "5.3"
        },
        {
            "name": "Blood lactate dehydrogenase increased",
            "percent": "5.3"
        },
        {
            "name": "Diarrhea",
            "percent": "8.7"
        },
        {
            "name": "Rigors",
            "percent": "8.7"
        },
        {
            "name": "Infusion site inflammation",
            "percent": "6.6"
        },
        {
            "name": "Urticaria",
            "percent": "6.5"
        },
        {
            "name": "Headache",
            "percent": "5.1-5.2"
        },
        {
            "name": "Chills",
            "percent": "2.7"
        },
        {
            "name": "Elevated temperature",
            "percent": "1.8"
        },
        {
            "name": "Fatigue",
            "percent": "1-1.8"
        },
        {
            "name": "Pyrexia",
            "percent": "1.5"
        },
        {
            "name": "Nausea",
            "percent": "1.5"
        },
        {
            "name": "Emesis",
            "percent": "1.3"
        },
        {
            "name": "Hypertension",
            "percent": "1"
        },
        {
            "name": "Flushing",
            "percent": "1"
        },
        {
            "name": "Sinusitis",
            "percent": "10"
        },
        {
            "name": "Nausea",
            "percent": "9"
        },
        {
            "name": "Acute sinusitis",
            "percent": "7"
        },
        {
            "name": "Fatigue",
            "percent": "7"
        },
        {
            "name": "Muscle spasms",
            "percent": "7"
        },
        {
            "name": "Bronchitis",
            "percent": "5"
        },
        {
            "name": "Diarrhea",
            "percent": "5"
        },
        {
            "name": "Nose bleed",
            "percent": "5"
        },
        {
            "name": "Muscle pain",
            "percent": "5"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "5"
        },
        {
            "name": "Pain in extremity",
            "percent": "5"
        },
        {
            "name": "Itching",
            "percent": "5"
        },
        {
            "name": "Chills",
            "percent": null
        },
        {
            "name": "Rigor",
            "percent": null
        },
        {
            "name": "Pain in extremity",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Migraine",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Leg cramps",
            "percent": null
        },
        {
            "name": "Flu",
            "percent": null
        },
        {
            "name": "like symptoms",
            "percent": null
        },
        {
            "name": "Exanthema",
            "percent": null
        },
        {
            "name": "Loss of appetite",
            "percent": null
        },
        {
            "name": "Anxiety",
            "percent": null
        },
        {
            "name": "Backache",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        },
        {
            "name": "Transient skin reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "eczema",
            "percent": null
        },
        {
            "name": "dermatitis",
            "percent": null
        }
    ]
}